The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

				OMB APPROVAL
UNI	OMB 3235- Number: 0076			
	Notice of Exempt	Offering of Secur	ities	Estimated average burden
				hours per response: 4.00
1. Issuer's Identity				
CIK (Filer ID Nur	nber) Previous Names	X None		Entity Type
<u>0001346302</u>			X Corporati	on
Name of Issue			Limited P	artnership
XERIS PHARMACEUTICA			Limited L	iability Company
Jurisdiction o				artnership
Incorporation/Organ DELAWARE	μεαιινιι		Business	
Year of Incorpora	tion/Organization		Other (Sp	ecify)
X Over Five Years Ago	uvii Vi Suinzativii			
Within Last Five Years (S	Specify Vear)			
Yet to Be Formed	pecify rear)			
2. Principal Place of Busines	s and Contact Information			
	of Issuer			
XERIS PHARMACEUTICA			Street Address 2	
3925 WEST BRAKER LAN	Address 1	THIRD FLOOI		
City	State/Province/Country			nber of Issuer
AUSTIN	TEXAS	78759	512-534-834	
3. Related Persons	-			
Last Name	Fire	st Name	Middle N	ame
Sabharwal	Yash			
Street Address 1	Street	Address 2		
3925 West Braker Lane	Third Floor			
City	State/Prov	/ince/Country	ZIP/Postal	Code
Austin	TEXAS		78759	
Relationship: X Executive	Officer Director Promote	er		
Clarification of Response (if	Necessary):			
Last Name	Firs	st Name	Middle N	ame
Kinzel	John		-	
Street Address 1	Street	Address 2		
3925 West Braker Lane	Third Floor			
City	State/Prov	/ince/Country	ZIP/Postal	Code
Austin	TEXAS		78759	

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Baum	Doug	
Street Address 1	Street Address 2	
3925 West Braker Lane	Third Floor	
City	State/Province/Country	ZIP/PostalCode
Austin	TEXAS	78759
Relationship: Executive Officer	X Director Promoter	
Clarification of Response (if Neces Last Name Prestrelski	sary): First Name Steven	Middle Name
Street Address 1	Steven Street Address 2	

ZIP/PostalCode

78759

3925 West Braker LaneThird FloorCityState/Province/CountryAustinTEXASRelationship: X Executive Officer X DirectorPromoter

Clarification of Response (if Necessary):

4. Industry Group

Electric Utilities

Oil & Gas

5. Issuer Size

Other Energy

Energy Conservation Environmental Services

Agriculture Banking & Financial Services Commercial Banking Insurance		Health Care Biotechnology Health Insurance	Retailing Restaurants Technology
Investing		Hospitals & Physicians Pharmaceuticals	Computers Telecommunications
Investment Banking Pooled Investment I	·	Other Health Care	Other Technology
Is the issuer registered as an investment company under the Investment Company Act of 1940?		Manufacturing Real Estate Commercial	Travel Airlines & Airports Lodging & Conventions
Yes	No	Construction	Tourism & Travel Services
Other Banking & Fi	nancial Services	REITS & Finance	Other Travel
Business Services Energy Coal Mining		Residential Other Real Estate	X Other

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000

X Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

		11 07		
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505			
Rule 504 (b)(1)(i)	X Rule 506			
Rule 504 (b)(1)(ii)		Act Section 4		
Rule 504 (b)(1)(iii)			ct Section 3(c)	
	Section 3(c		Section 3(c)(9)	
	Section 3(c	2)(2)	Section 3(c)(10)	
	Section 3(c	2)(3)	Section 3(c)(11)	
	Section 3(c	c)(4)	Section 3(c)(12)	
	Section 3(c	c)(5)	Section 3(c)(13)	
	Section 3(c	c)(6)	Section 3(c)(14)	
	Section 3(c)(7)		
7. Type of Filing				
New Notice Date of First Sale 2011-07-05	First Sale Yet t	o Occur		
X Amendment				
8. Duration of Offering				
Does the Issuer intend this offering to last more	than one year?	Yes X No		
9. Type(s) of Securities Offered (select all that ap	oply)			
X Equity		Pooled I	nvestment Fund Interests	
Debt			n-Common Securities	
X Option, Warrant or Other Right to Acquire Ar			Property Securities	
X Security to be Acquired Upon Exercise of Op Other Right to Acquire Security	tion, warrant or	Other (de	escribe)	
10. Business Combination Transaction				
Is this offering being made in connection with a a merger, acquisition or exchange offer?	business combi	nation transa	ction, such as Yes X No	
Clarification of Response (if Necessary):				
11. Minimum Investment				
Minimum investment accepted from any outside	investor \$0 US	D		
12. Sales Compensation				
Recipient	Rec	ipient CRD I	Number X None	
(Associated) Broker or Dealer X None	(Ass	sociated) Bro	ker or Dealer CRD Number X Nor	ne
Street Address 1			Street Address 2	
City	State	e/Province/C	ountry	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	All States Fo	oreign/non-U	S	
13. Offering and Sales Amounts				
Total Offering Amount \$1,958,748 USD or	Indefinite			

Total Amount Sold \$1,837,848 USD

Total Remaining to be Sold \$120,900 USD or Indefinite

Clarification of Response (if Necessary):

Series A Preferred Stock Financing and Issuance of Series A Preferred Stock Warrants exercisable at \$1.02 per share.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

19		

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
XERIS PHARMACEUTICALS INC	/s/John Kinzell	John Kinzell	Chief Executive Officer	2011-10-11

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.